MRK - NYSE
Merck & Co., Inc.
$114.80
-0.36%Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
At a Glance
Live SnapshotMerck & Co., Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Moderate capital requirements typical of many stable businesses. Healthy balance between reinvestment and cash generation.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Merck & Co., Inc. Cash Flow Statement
MRK • NYSE
| Merck & Co., Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
18.3B | 17.1B | 365M | 14.5B | 12.4B | 7.1B | 9.8B | 6.2B | 2.4B | 3.9B | 4.5B | 11.9B | 4.5B | 6.3B | 6.4B | 982M | 13B | 7.8B | 3.3B | 4.4B | |
5.8B | 4.5B | 3.9B | 3.9B | 3.2B | 3.6B | 3.7B | 4.5B | 4.6B | 5.4B | 6.4B | 6.7B | 7B | 7B | 7.4B | 7.4B | 2.6B | 1.6B | 2B | 2.3B | |
-1.7B | -1.2B | -1.9B | -1.6B | 187M | -668M | -556M | -509M | -2.6B | -1.5B | -764M | -2.6B | -330M | 669M | -1.5B | -1.1B | 1.8B | 530.1M | -1.8B | -530.2M | |
0.0 | 761M | 645M | 541M | 479M | 441M | 417M | 348M | 312M | 300M | 299M | 278M | 276M | 335M | 369M | 509M | 415.5M | 219M | 211M | 168M | |
1B | 4B | 12.2B | 4.5B | 1.7B | 4.4B | 2.2B | 1.9B | 6.7B | 4.8B | 2.3B | -10.3B | 997M | -123M | 498M | 2.1B | -11.7B | 367M | 2B | 562.6M | |
-7B | -3.7B | -2.2B | -2.8B | -3.8B | -4.6B | -2.1B | -1.6B | -5B | -2.6B | -268M | 1.8B | -794M | -4.1B | -766M | 930M | -2.7B | -4B | 1.4B | -137.4M | |
16.5B | 21.5B | 13B | 19.1B | 14.1B | 10.3B | 13.4B | 10.9B | 6.4B | 10.4B | 12.4B | 7.9B | 11.7B | 10B | 12.4B | 10.8B | 3.4B | 6.6B | 7B | 6.8B | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-4.1B | -3.4B | -3.9B | -4.4B | -4.4B | -4.7B | -3.5B | -2.6B | -1.9B | -1.6B | -1.3B | -2.3B | -1.5B | -2B | -1.7B | -1.7B | -1.5B | -1.3B | -1B | -980.2M | |
-10B | -4.1B | -12B | -121M | -12.9B | -6.6B | -5B | -431M | -396M | -780M | -7.4B | (11.2B) | -200M | (2B) | -50M | (391M) | -9B | (0.0) | -1.1B | (0.0) | |
-1.2B | -519M | -955M | -1.2B | -1M | -1.1B | -3.2B | -8B | -10.7B | -15.7B | -16.7B | -24.9B | -18B | -12.8B | -7.3B | -7.2B | -3.1B | -12B | -10.1B | -20B | |
1.7B | 377M | 1.7B | 721M | 1B | 2.8B | 8.6B | 15.3B | 15.7B | 14.4B | 20.4B | 15.5B | 16.3B | 7.8B | 6.3B | 4.6B | 10.9B | 11.1B | 10.9B | 16.1B | |
-58M | -127M | 1.1B | 32M | -225M | 130M | 378M | 102M | 38M | 482M | 221M | 115M | 293M | -1.7B | -116M | 426M | 5.7B | 365.4M | -1.4B | -3M | |
-13.7B | -7.7B | -14.1B | -5B | -16.6B | -9.4B | -2.6B | (4.3B) | (2.7B) | -3.2B | -4.8B | -374M | -3.1B | -6.8B | -2.9B | -3.5B | (3.2B) | -1.8B | -2.8B | -4.9B | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-5B | -1.3B | -1.3B | 384M | -840M | -1.3B | -4.8B | -9.1B | -4B | -3.4B | -4.2B | -7.7B | -6.5B | -2.6B | -1.9B | -1.6B | 0.0 | -2.7B | -531.1M | -632.4M | |
11.4B | 2.3B | 4.2B | -2.3B | 1.6B | 5B | 1.2B | 837M | -1.1B | -1.3B | 3.5B | -3.5B | 4.5B | 3.2B | -471M | 748M | 1.8B | 468M | -1.2B | -1.3B | |
-8.2B | -7.8B | -7.4B | -7B | -6.6B | -6.2B | -5.7B | -5.2B | -5.2B | -5.1B | -5.1B | -5.2B | -5.3B | -5.2B | -4.8B | -4.9B | -3.5B | -3.3B | -3.3B | -3.3B | |
-5.1B | -1.3B | -1.3B | (0.0) | -840M | -1.3B | -4.8B | -9.1B | -4B | -3.4B | -4.2B | -7.7B | -6.5B | -2.6B | -1.9B | -1.6B | (0.0) | -2.7B | -1.4B | -1B | |
-131M | -195M | -203M | -240M | 8.4B | -347M | 366M | 266M | 304M | 821M | 424M | 1.2B | 1.2B | 1.4B | -22M | -106M | 59.7M | 13M | 156.2M | -375.3M | |
-1.9B | -7B | -4.8B | -9.1B | 2.6B | -2.8B | -8.9B | -13.2B | -10B | -9B | -5.4B | -15.1B | -6B | -3.3B | -6.9B | -5.4B | -1.6B | -5.5B | -4.9B | -5.6B | |
CASH FLOW SUMMARY | ||||||||||||||||||||
563M | -293M | 23M | -410M | -133M | 253M | 17M | -205M | 457M | -131M | -1.3B | -553M | -346M | -30M | 42M | -295M | 33.4M | -182.6M | 98.3M | 52.1M | |
1.4B | 6.4B | -5.9B | 4.6B | 14M | -1.8B | 2B | 1.9B | -423M | -2B | 1.1B | -8.2B | 2.2B | -80M | 2.6B | 1.6B | 4.9B | -967.8M | -578.6M | -3.7B | |
13.3B | 6.9B | 12.8B | 8.2B | 8.2B | 9.9B | 8B | 6.1B | 6.5B | 8.5B | 7.4B | 15.6B | 13.5B | 13.5B | 10.9B | 9.3B | 4.4B | 5.3B | 5.9B | 9.6B | |
14.7B | 13.3B | 6.9B | 12.8B | 8.2B | 8.2B | 9.9B | 8B | 6.1B | 6.5B | 8.5B | 7.4B | 15.6B | 13.5B | 13.5B | 10.9B | 9.3B | 4.4B | 5.3B | 5.9B | |
12.4B | 18.1B | 9.1B | 14.7B | 9.7B | 5.6B | 10B | 8.3B | 4.6B | 8.8B | 11.1B | 5.5B | 10.1B | 8.1B | 10.7B | 9.1B | 1.9B | 5.3B | 6B | 5.8B |
SEC Filings
MRK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 28, 2026 | May 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 22, 2026 | May 22, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 08, 2026 | May 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 03, 2026 | February 03, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 04, 2025 | December 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 |
Related Guides
Continue your MRK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.